Ropeginterferon versus Standard Therapy for Low-Risk Patients with Polycythemia Vera
Ropeginterferon for Patients with Polycythemia VeraPatients with low-risk polycythemia vera were randomly assigned to receive ropeginterferon alfa-2b and phlebotomy or phlebotomy alone. The trial met its end point of maintenance of a hematocrit target (≤45%) without thrombotic events, progression of leukocytosis, thrombocytosis, and worsening of splenomegaly in the ropeginterferon alfa-2b group.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:2 |
|---|---|
| Enthalten in: |
NEJM evidence - 2(2023), 6 vom: 31. Juni, Seite EVIDoa2200335 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 08.02.2024 Date Revised 08.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1056/EVIDoa2200335 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368095177 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368095177 | ||
| 003 | DE-627 | ||
| 005 | 20240208232111.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240207s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1056/EVIDoa2200335 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1284.xml |
| 035 | |a (DE-627)NLM368095177 | ||
| 035 | |a (NLM)38320126 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Barbui, Tiziano |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Ropeginterferon versus Standard Therapy for Low-Risk Patients with Polycythemia Vera |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.02.2024 | ||
| 500 | |a Date Revised 08.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Ropeginterferon for Patients with Polycythemia VeraPatients with low-risk polycythemia vera were randomly assigned to receive ropeginterferon alfa-2b and phlebotomy or phlebotomy alone. The trial met its end point of maintenance of a hematocrit target (≤45%) without thrombotic events, progression of leukocytosis, thrombocytosis, and worsening of splenomegaly in the ropeginterferon alfa-2b group | ||
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Vannucchi, Alessandro Maria |e verfasserin |4 aut | |
| 700 | 1 | |a De Stefano, Valerio |e verfasserin |4 aut | |
| 700 | 1 | |a Carobbio, Alessandra |e verfasserin |4 aut | |
| 700 | 1 | |a Ghirardi, Arianna |e verfasserin |4 aut | |
| 700 | 1 | |a Carioli, Greta |e verfasserin |4 aut | |
| 700 | 1 | |a Masciulli, Arianna |e verfasserin |4 aut | |
| 700 | 1 | |a Rossi, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Ciceri, Fabio |e verfasserin |4 aut | |
| 700 | 1 | |a Bonifacio, Massimiliano |e verfasserin |4 aut | |
| 700 | 1 | |a Iurlo, Alessandra |e verfasserin |4 aut | |
| 700 | 1 | |a Palandri, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Benevolo, Giulia |e verfasserin |4 aut | |
| 700 | 1 | |a Pane, Fabrizio |e verfasserin |4 aut | |
| 700 | 1 | |a Ricco, Alessandra |e verfasserin |4 aut | |
| 700 | 1 | |a Carli, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Caramella, Marianna |e verfasserin |4 aut | |
| 700 | 1 | |a Rapezzi, Davide |e verfasserin |4 aut | |
| 700 | 1 | |a Musolino, Caterina |e verfasserin |4 aut | |
| 700 | 1 | |a Siragusa, Sergio |e verfasserin |4 aut | |
| 700 | 1 | |a Rumi, Elisa |e verfasserin |4 aut | |
| 700 | 1 | |a Patriarca, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Cascavilla, Nicola |e verfasserin |4 aut | |
| 700 | 1 | |a Mora, Barbara |e verfasserin |4 aut | |
| 700 | 1 | |a Cacciola, Emma |e verfasserin |4 aut | |
| 700 | 1 | |a Mannarelli, Carmela |e verfasserin |4 aut | |
| 700 | 1 | |a Loscocco, Giuseppe Gaetano |e verfasserin |4 aut | |
| 700 | 1 | |a Guglielmelli, Paola |e verfasserin |4 aut | |
| 700 | 1 | |a Gesullo, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Betti, Silvia |e verfasserin |4 aut | |
| 700 | 1 | |a Lunghi, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Scaffidi, Luigi |e verfasserin |4 aut | |
| 700 | 1 | |a Bucelli, Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Vianelli, Nicola |e verfasserin |4 aut | |
| 700 | 1 | |a Bellini, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a Finazzi, Maria Chiara |e verfasserin |4 aut | |
| 700 | 1 | |a Tognoni, Gianni |e verfasserin |4 aut | |
| 700 | 1 | |a Rambaldi, Alessandro |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t NEJM evidence |d 2022 |g 2(2023), 6 vom: 31. Juni, Seite EVIDoa2200335 |w (DE-627)NLM339641495 |x 2766-5526 |7 nnns |
| 773 | 1 | 8 | |g volume:2 |g year:2023 |g number:6 |g day:31 |g month:06 |g pages:EVIDoa2200335 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1056/EVIDoa2200335 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 2 |j 2023 |e 6 |b 31 |c 06 |h EVIDoa2200335 | ||